Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data were shared through one oral and two poster sessions, underscoring the company's progress in developing novel cancer therapies.
TNX-1700, a potential treatment for gastric cancer, demonstrated the ability to reduce inflammation and tumor progression in preclinical models. The compound also showed favorable pharmacokinetics, suggesting it could be a viable candidate for further development. Gastric cancer remains a significant unmet medical need, with limited treatment options for advanced stages.
TNX-4700, a monoclonal antibody targeting BTLA (B- and T-lymphocyte attenuator), showed promising in vitro activity. BTLA is an immune checkpoint receptor that inhibits T-cell activation, and targeting it may enhance anti-tumor immune responses. The data support TNX-4700's potential as a single agent or in combination with other checkpoint inhibitors, such as anti-PD-1 therapies, to improve cancer immunotherapy outcomes.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company with a focus on central nervous system (CNS) and immunology treatments. Its recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is advancing TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, and its CNS pipeline includes TNX-2900 for Prader-Willi syndrome.
In immunology, Tonix is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection. The AACR presentation highlights the company's expanding efforts in immuno-oncology, leveraging its expertise in antibody engineering and immune modulation.
The full press release is available at https://ibn.fm/Oly6o. For more information on Tonix Pharmaceuticals, visit their newsroom at https://ibn.fm/TNXP.
